Related Experiment Videos

[Pediatric pharmacology of azlocilin (author's transl)]

Padiatrie Und Padologie
|January 1, 1979
PubMed

Insights

Azlocillin pharmacokinetics vary by age, with longer serum half-lives in newborns. Clinical use showed better outcomes for urinary tract infections than respiratory infections due to bacterial persistence.

Area of Science:

  • Pharmacology
  • Microbiology
  • Pediatrics

Context:

  • Acylureido-penicillin pharmacokinetics, specifically azlocillin, exhibit age-dependent variability.
  • Significant differences in serum half-life were observed between newborns (2.56 hours) and school children (0.94 hours).

Purpose:

  • To investigate the pharmacokinetics of azlocillin across different pediatric age groups.
  • To evaluate the clinical efficacy and tolerance of azlocillin in treating bacterial infections in children.

Summary:

  • Pharmacokinetic studies revealed prolonged azlocillin serum half-life in newborns compared to older children.
  • Clinical application in 29 patients with Pseudomonas aeruginosa and Proteus mirabilis infections demonstrated varied efficacy.
  • Urinary tract infections responded better to azlocillin than respiratory tract infections, possibly due to bacterial persistence in bronchial secretions.

Impact:

  • Provides crucial pharmacokinetic data for age-specific azlocillin dosing in pediatric populations.
  • Highlights potential challenges in treating respiratory infections due to bacterial persistence despite effective drug levels.
  • Suggests azlocillin is well-tolerated in pediatric patients.

Related Concept Videos